PI Pharma Insight

BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Reset

Active filters

  • Product: Tapentadol
Presentation Product Chemical substance Chapter Items dispensed
Tapentadol 50mg modified-release tablets
0407020AGAAACAC
Tapentadol Tapentadol Central Nervous System 12,889
Tapentadol 100mg modified-release tablets
0407020AGAAADAD
Tapentadol Tapentadol Central Nervous System 10,293
Tapentadol 50mg tablets
0407020AGAAAAAA
Tapentadol Tapentadol Central Nervous System 9,707
Tapentadol 150mg modified-release tablets
0407020AGAAAEAE
Tapentadol Tapentadol Central Nervous System 4,204
Tapentadol 200mg modified-release tablets
0407020AGAAAFAF
Tapentadol Tapentadol Central Nervous System 4,025
Tapentadol 250mg modified-release tablets
0407020AGAAAGAG
Tapentadol Tapentadol Central Nervous System 1,936
Tapentadol 25mg modified-release tablets
0407020AGAAAIAI
Tapentadol Tapentadol Central Nervous System 728
Tapentadol 75mg tablets
0407020AGAAABAB
Tapentadol Tapentadol Central Nervous System 668
Tapentadol 20mg/ml oral solution sugar free
0407020AGAAAHAH
Tapentadol Tapentadol Central Nervous System 222
Tapentadol 50mg modified-release capsules
0407020AGAAAJAJ
Tapentadol Tapentadol Central Nervous System 14
Tapentadol 100mg modified-release capsules
0407020AGAAAKAK
Tapentadol Tapentadol Central Nervous System 10
Tapentadol 150mg modified-release capsules
0407020AGAAALAL
Tapentadol Tapentadol Central Nervous System 9
Tapentadol 200mg modified-release capsules
0407020AGAAAMAM
Tapentadol Tapentadol Central Nervous System 3
Tapentadol 250mg modified-release capsules
0407020AGAAANAN
Tapentadol Tapentadol Central Nervous System 1
Tapentadol 100mg tablets
0407020AGAAAPAP
Tapentadol Tapentadol Central Nervous System No data available

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.